Expression and Effect of Inhibition of the Ubiquitin-Conjugating Enzyme E2C on Esophageal Adenocarcinoma  by Lin, Jules et al.
Expression and Effect of Inhibition of the Ubiquitin-Conjugating
Enzyme E2C on Esophageal Adenocarcinoma1
Jules Lin*, Duna A. Raoof*, Zhuwen Wang*, Mu-Yen Lin y, Dafydd G. Thomasz, Joel K. Greenson z,
Thomas J. Giordano z, Mark B. Orringer*, Andrew C. Chang*, David G. Beer* and Lin Lin*
*Section of General Thoracic Surgery, Department of Surgery, University of Michigan Medical School,
Ann Arbor, MI, USA; yDivision of Thoracic Surgery, Department of Surgery and Institute of Clinical Medicine,
College of Medicine, National Cheng Kung University, Tainan, Taiwan; zDepartment of Pathology, University
of Michigan Medical School, Ann Arbor, MI, USA
Abstract
Ubiquitin-dependent proteolysis of cyclins plays a criti-
cal role in cell cycle progression and tumorigenesis.
We examined the expression of ubiquitin-conjugating
enzymeE2C (UBE2C) during progression fromBarrett’s
metaplasia to esophageal adenocarcinoma (EA) and
the effects of targeting this enzyme on EA-derived cell
lines. Using oligonucleotide microarrays UBE2C ex-
pression was elevated in 73% (11 of 15) of EAs relative
to Barrett’s metaplasia. Tissue microarray showed
elevated UBE2C in 70% (7 of 10) of dysplastic samples
and in 87% (58 of 67) of tumors relative to metaplastic
samples. Transfection of dominant-negative UBE2C
into Seg-1 cells decreased proliferation (P = .04) and
increased mitotic arrest compared to vector controls
(63.5% vs 6.8%; P < .001). Transfection of UBE2C small
interfering RNA also caused inhibiton of cell prolifer-
ation and distortion of the cell cycle, with maximal in-
crease of G2 cells (155% of mock cells) at 72 hours and
of S-phase cells (308% of mock cells) at 24 hours.
Treatment of Seg-1 cells with the proteasome inhibitor
MG-262 (1 nM–1 MM) showed decreased proliferation
(P = .02). EA-derived cells expressing UBE2C are
sensitive to treatment with MG-262 and to silencing
of UBE2C, suggesting that patients with EAs over-
expressing UBE2C may benefit from agents targeting
this ubiquitin-conjugating enzyme.
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Introduction
Targeted destruction of regulatory proteins, including cyclin B
and securin, is important in cell cycle progression [1,2].
Destruction of cyclin B inactivates cdc2 kinase, allowing cells
to exit mitosis, whereas destruction of securin releases
separase, leading to anaphase and separation of chro-
matids. This targeted destruction is mediated by the ubiqui-
tin/proteasome system. This involves the activity of three
enzymes, including ubiquitin-activating enzymes (E1), which
activate ubiquitin and transfer it to a ubiquitin-conjugating
enzyme (E2). E2 then transfers ubiquitin to the target protein,
often with the help of a ubiquitin-ligating enzyme (E3). The poly-
ubiquitinated protein is then recognized by 26S proteasome for
destruction. Although E1 and ubiquitin are highly conserved,
various E2 and E3 enzymes provide substrate specificity [3,4].
The ubiquitin-conjugating enzyme E2C (UBE2C), also
known as UBCH10, along with the E3 ligase of the anaphase-
promoting complex (APC), catalyzes the ubiquitination of mi-
totic cyclins A and B, as well as securin. UBE2C is essential for
cell cycle progression, and mutation of its active site cysteine
confers a dominant-negative phenotype [5,6]. Overexpression
of UBE2C at the mRNA level has been reported by Okamoto
et al. [7] in a number of cancer cell lines and primary tumors,
including lung, gastric, bladder, and uterine cancers, whereas
only low levels were found in normal tissues. Takahashi et al. [8]
suggest that overexpression of UBE2C may play an important
role in advanced colon cancer with liver metastasis and that
this overexpression may be a result of chromosomal amplifi-
cation at the UBE2C locus, 20q13.1. In addition, NIH3T3 cells
transfected with UBE2C showed an increase in growth rate
and colony formation, suggesting that UBE2C is important in
promoting cell growth and transformation. The level of UBE2C is
also upregulated after NIH3T3 cells are transformed by an
EWS–FL11 fusion gene from Ewing’s sarcoma [9].
Over the past two decades, the incidence of esophageal
adenocarcinoma has increased greatly, whereas the 5-year
survival remains low at < 10% [10,11]. Although esophagec-
tomy remains the primary means of treatment, there is an ur-
gent need for both novel therapies and early detectionmethods.
The present study was undertaken to delineate the expression
of UBE2C in esophageal adenocarcinoma and to investigate
this enzyme as a potential target against this deadly cancer.
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Materials and Methods
Patients and Tissues
After obtaining informed consent, tissues were obtained
from patients undergoing esophagectomy for adenocarcinoma
at the University of Michigan Medical Center (Ann Arbor, MI)
and transported to the laboratory in Dulbecco’s modified
Eagle’s medium (DMEM; Life Technologies, Inc., Carlsbad,
CA) on ice. A portion of each sample was embedded on OCT
compound (Miles, Inc., Elkhart, IN) and frozen in isopentane
cooled in liquid nitrogen for cryostat sectioning. The remainder
was frozen in liquid nitrogen and stored at80jC.Metaplastic
or dysplastic mucosa and tumor samples with at least 70%
cellularity were identified using hematoxylin and eosin–
stained frozen sections, and 2-mm3 samples were obtained
for RNA and protein isolation using microdissection on the
original piece of tissue. The sections were then examined
by two pathologists (T.J.G. and J.K.G.) to confirm the histo-
pathological diagnosis of esophageal adenocarcinoma, high-
grade or low-grade dysplasia, Barrett’s metaplasia, or normal
esophageal mucosa.
Cell Lines
Nine esophageal cell lines were used. OE33 [12], Seg-1,
Bic-1, and Flo-1 were derived from esophageal adeno-
carcinoma and have been described previously [13]. H80-T,
L20-T, and BA1 also originated from esophageal adeno-
carcinoma, whereas S95-B was derived from Barrett’s meta-
plasia following immortalization with E6/E7 retroviral
infection. BA1 was kindly provided by Dr. Michael Rutten
(OregonHealth andScienceUniversity, Portland, OR). Het-1A
is an esophageal squamous cell line immortalized by SV40
infection [14]. All cell lines were grown in DMEM (Life Tech-
nologies, Inc.) supplemented with 10% fetal bovine serum
(FBS; Atlanta Biologicals, Norcross, GA) and 1% penicillin/
streptomycin/fungizone (Life Technologies, Inc.) at 37jC in
5% CO2/95% air.
Oligonucleotide Microarray
Total RNA was isolated from 50 esophageal samples
using Trizol (Life Technologies, Inc.) and purified with
RNeasy spin columns (Qiagen, Valencia, CA) according to
the manufacturer’s instructions. RNA quality was confirmed
by 1% agarose gel electrophoresis and A260/A280 spectro-
photometer ratios. RNA quality was reassessed with Agilent
Bioanalyzer (Agilent Technologies, Palo Alto, CA) at inter-
mediate steps after double-stranded cDNA and cRNA syn-
theses. Four samples were excluded due to insufficient
quantity of RNA (< 10 mg). cDNA synthesis, cRNA amplifica-
tion, hybridization, and washing of HG-U133B Gene Chips
(Affymetrix, Santa Clara, CA) were performed by the Univer-
sity of Michigan Cancer Center Microarray Core according to
the manufacturer’s instructions.
To normalize microarray data, a summary statistic was
calculated using 11 probe pairs for each gene and the robust
multichip average method [15], as implemented in the Affy-
metrix Library of Bioconductor (version 1.3, www.bioconductor.
org), which provides background adjustment, quantile nor-
malization, and summarization. Expression values for each
sample were then compared to the mean expression value
for the seven Barrett’s metaplasia samples. A fold change of
> 2.0 was considered significant, as previously described [16].
Western Blot Analysis
Western blot analysis was performed as previously de-
scribed, with slight modifications [13]. Briefly, a 1:500 or
1:1000 dilution of a UBE2C antibody (catalog no. AB3861,
rabbit polyclonal antibody; Chemicon International, Teme-
cula, CA) and a 1:5000 dilution of goat anti-rabbit secondary
antibody (catalog no. PI-1000; Vector Laboratories, Inc.,
Burlingame, CA) were used for protein detection. Western
blot membrane was stripped (2 M glycine, pH 2.5, at room
temperature for 30 minutes), and b-actin expression was
determined with a 1:1000 or 1:5000 dilution of anti–b-actin
antibody (catalog no. ab6276; Abcam, Inc., Cambridge, MA)
and a 1:10,000 dilution of goat anti-mouse monoclonal sec-
ondary antibody (catalog no. ab6785; Abcam, Inc.) used as
loading control.
Immunohistochemistry and Tissue Microarray (TMA)
TMA was constructed, as previously described [17], with
formalin-fixed paraffin-embedded tissues. Immunohisto-
chemical staining was performed using DAKO LSAB+ kit
(DAKO, Carpinteria, CA) and diaminobenzidine as chroma-
gen. Dewaxed and rehydrated sections of the TMA at 4 mm
thickness were labeled with UBE2C antibody (Abcam, Inc.)
at a 1:100 dilution after microwave citric acid epitope retrieval
for 20 minutes.
The UBE2C antibody from Chemicon International was
unsuitable for immunohistochemistry and was used only for
Western blot analysis. Slides were lightly counterstained with
hematoxylin. Each sample was then scored 0, 1, 2, or 3 cor-
responding to absent, light, moderate, or intense staining. To
be conservative, only samples with moderate to intense
staining were considered significant.
Expansion and Purification of Dominant-Negative UBE2C
pJS55 plasmid–encoding mutant (C114S) UBE2C was
kindly provided by Dr. J. V. Ruderman (Harvard Medical
School, Boston, MA) [5]. The sequence encoding the
dominant-negative UBE2C was subcloned into a pSG5
vector (Stratagene, La Jolla, CA) at EcoRI and Bgl II re-
striction sites using standard techniques. UBE2C–pSG5
construct was then expanded in AG1 bacteria (Stratagene)
according to the manufacturer’s instructions. Individual colo-
nies grown on LB plates were collected and grown overnight
in LB medium containing ampicillin (100 mg/ml) and chloram-
phenicol (34 mg/ml) at 37jC with continuous shaking. DNA
purification was performed using the QIAprep Spin Miniprep
Kit (Qiagen) according to the manufacturer’s instructions.
The dominant-negative UBE2C insert was confirmed by
DNA sequencing and enzymatic digest. Sequencing was
performed by the University of Michigan DNA Sequencing
Core using an ABI Prism Gene Analyzer (Model 3700;
Applied Biosystems, Foster City, CA). Forward and reverse
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primers 5V-CGTGCTGGTTATTGTGCTGTC-3V and 5V-
GTGAAATTTGTGATGCTATTGCT-3V were used. A double-
enzymatic digest was also performed with EcoRI/HindIII
andNdeI using standard techniques. Products were resolved
on a 1% agarose gel with ethidium bromide (0.25 mg/ml), and
products were visualized with UV transillumination. After
the insert had been confirmed, the bacteria were further ex-
panded in LB medium overnight, and the dominant-negative
plasmid was isolated using the High Purity Plasmid Maxiprep
System (Marligen Biosciences, Ijamsville, MD) according to
the manufacturer’s instructions.
MTT and WST-1 Cell Proliferation Assays
Cell viability and cell proliferation were assessed using
MTT assay (ATCC, Manassas, VA) or Cell Proliferation
Reagent WST-1 (Roche Applied Science, Indianapolis, IN)
according to the manufacturer’s instructions. All experiments
for dominant-negative UBE2C transfection and small inter-
fering RNA (siRNA)–mediated silencing UBE2C were re-
peated in triplicate (MTT) or quadruplicate (WST-1). For
WST-1 analysis, assays were performed in two different
densities: 1.5 103 and 2.5 103 cells/well in 96-well format.
Transfection of Seg-1 Cells with Dominant-Negative UBE2C
Seg-1 cultures at 70% confluence were trypsinized, and
cells were transferred to 96-well plates. Each well contained
2  103 cells and was incubated for 24 hours in DMEM (Life
Technologies, Inc.) with 10% FBS (Atlanta Biologicals) and
1% penicillin/streptomycin/fungizone (Life Technologies,
Inc.). Transfection with dominant-negative UBE2C plas-
mids was performed using Fugene 6 Transfection Reagent
(Roche Applied Science) according to the manufacturer’s
instructions using a 3:2 Fugene/DNA ratio. Cells were al-
lowed to grow for 48 hours. Cell viability was then assessed
using the MTTassay (ATCC). All experiments were repeated
in triplicate.
To determine the mitotic index, cell cultures were trypsin-
ized and cytospun onto poly-L-lysine–coated slides. Cells
that were successfully transfected could be identified by
expression of the AU1 epitope, which was included in the
UBE2C insert. Immunohistochemical staining was performed
as described above using an AU1 polyclonal antibody (Co-
vance, Princeton, NJ) at a 1:400 dilution. Cells were then
examined under lightmicroscopy. Transfection efficiencywas
determined by dividing the number of cells that stained
positive for AU1 by the total number of cells per high-power
field. Themitotic index was calculated by dividing the number
of mitotic figures in AU1-positive cells by the total number of
cells expressing the AU1 protein. All experiments were
repeated in triplicate.
Treatment of Cell Cultures with the Proteasome
Inhibitor MG-262
Cell culture treatments were performed as previously
described [18–21]. Briefly, once Seg-1 cultures had reached
70% confluence, they were trypsinized and transferred to
96-well plates. Each well was plated with 2  103 cells and
incubated for 24 hours in DMEM (Life Technologies, Inc.) with
10% FBS (Atlanta Biologicals) and 1% penicillin/strepto-
mycin/fungizone (Life Technologies, Inc.). Cells were then
treated with 1 nM to 1 mM MG-262 (Biomol International,
Plymouth Meeting, PA) as previously described [22–24].
Control cultures were treated with an equivalent amount of
distilled water. Cells were allowed to grow for 48 hours. Cell
viability was then assessed using the MTTassay (ATCC). All
experiments were repeated in triplicate.
UBE2C Silencing By Transfection of Gene-Specific siRNA
All SMARTpool siRNA reagents were purchased from
Dharmacon (Lafayette, CO). Trial experiments were per-
formed before actual siRNA assays to determine optimal
cell densities, different sources of transfection reagents,
ratios of transfection reagents, and siRNA cell toxicity for
siRNA gene knockdown efficiency and transfection effi-
ciency. Cell toxicity was assessed using cells stained with
trypan blue. Twenty-four hours before siRNA transfection,
Seg-1 cells were seeded in quadruplicate at densities of 1.5
103, 2.5 103, 3.5 103, and 4.5 103 cells/well with 100 ml
of DMEM with 10% FBS but without antibiotics. For siRNA
transfection, we added two reactants to each well of the
96-well format. Reaction tube 1 contained 9.5 ml of Opti-
MEM I (Invitrogen, Carlsbad, CA) and 0.5 ml of 2 pmol/ml
(2000 nM) SMARTpool siRNA (UBE2C or Lamin A/C as
positive control or siCONTROL nontargeting siRNA no. 2
as negative control) (Dharmacon). Reaction tube 2 contained
0.1 ml of Lipofectamine RNAiMAX (Invitrogen) diluted in
9.9 ml of Opti-MEM I. The two reactants were incubated at
room temperature for 5 minutes, respectively. siRNA and
Lipofectamine RNAiMAX were then combined and incubated
for 20 minutes at room temperature. siRNA Lipofectamin
RNAiMAX complexes were pipetted into each well containing
Seg-1 cells, with an siRNA working concentration of 10 nM.
Transfected cells were incubated for 24 to 96 hours at 37jC
before gene silencing analysis.
Real-Time Reverse Transcription–Polymerase Chain
Reaction (RT-PCR) for Quantitative Measurement of
UBE2C Expression after siRNA-Mediated Gene Silencing
Cells from four wells at each cell density were harvested at
various time points, and total RNA was extracted using an
RNeasy Mini Kit (Qiagen) according to the manufacturer’s
instruction. Real-time RT-PCR was performed using the
Smart Cycler System (Cepheid, Sunnyvale, CA) with Plati-
num SYBR Green kit (Invitrogen). A standard curve of each
targeted gene was generated with a series of dilutions (20.0,
2.0, 0.2, 0.02, and 0.0 ng) from a reference cDNA con-
verted from total RNA using the Superscript II kit (Invitrogen).
Primer sequences for real-timeRT-PCR forUBE2C, a 132-bp
PCR product crossing UBE2C exons 5 and 6, are UB2-5f
5V-ctg ccg agc tct gga aaa ac-3V and UB2-6r 5V-agg aaa aat
taa aaa gac gac aca ag-3V. The primers for Lamin A/C, a 145-
bp PCR product crossing exons 2 and 3, are lmnaE2F 5V-aag
gag gcc gca ctg agc act g-3V and lmnaE3R 5V-cca ccc gcc
gca gca tct c-3V. Optimal annealing temperature was deter-
mined, and melt curve was closely analyzed to ensure real-
time PCR results.
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Flow Cytometry of Seg-1 Cells Transfected
after siRNA-Mediated UBE2C Silencing
Seg-1 cells grown in six-well culture plateswere transfected
with UBE2C-specific siRNA and harvested at 24, 48, 72, and
96 hours, respectively. Two other 72-hour to and 96-hour
transfectants were also collected, each with an additional
UBE2C-specific siRNA transfection at the 48-hour time point.
For propidium iodine (PI) cell staining, cells were harvested
by trypsinization and washed twice in ice-cold PBS. Cells were
then resuspended at 106 cells/0.5 ml of PBS and fixed by
dropwise addition of 1.17 ml of cold 100% methanol while
vortexing. Cells were fixed for 20 minutes on ice and stored
at 4jC before PI staining and flow cytometric analysis. For
flow cytometry, cells were pelleted at 1000 rpm for 5 to 7 min-
utes at 4jC, washed with cold PBS and 1 ml of propidium
iodide (PI) staining solution (50 mg/ml PBS) added to the cell
pellet, andmixed. Fifty microliters of RNase A (100 mg/ml) was
then added and incubated with the cells for 1 hour at room
temperature in the dark. Flow cytometric analysis was per-
formed at the University of Michigan Flow Cytometry Core.
Cells transfected with UBE2C-specific siRNA were also
subjected to mitotic index analysis, as mentioned above. Cell
cultures were trypsinized and cytospun onto poly-L-lysine–
coated slides as described above. Mitotic cells were counted
from enlarged microscopically obtained images.
Statistical Analysis
Statistical analysis was performed by comparing the ex-
perimental group to control cultures using a two-sided Stu-
dent’s t test.
Results
UBE2C mRNA Is Overexpressed in Barrett’s Dysplasia
and Adenocarcinoma
Oligonucleotide microarrays were used to analyze a co-
hort of 46 esophageal samples revealing at least a two-fold
overexpression in esophageal adenocarcinoma relative to
Barrett’s metaplasia for UBE2C in 11 of 15 (73%) samples
(Figure 1). Overexpression of UBE2C was also found in one
of seven (14%) high-grade dysplasia samples and in one of
eight (13%) low-grade dysplasia samples.
UBE2C Protein Expression on TMA
Staining of UBE2C protein was determined on a variety of
esophageal tissue samples using UBE2C antibody on a TMA
(Table 1). Significant UBE2C protein expression was found in
58 of 67 (87%) of esophageal adenocarcinoma samples
(Figure 2, A and B). Seventy percent (7 of 10) of dysplastic
samples (Figure 2C) showed significant UBE2C protein
staining, whereas none of the Barrett’s metaplasia samples
was positive (Figure 2D). In addition, seven of eight (88%)
samples of lymph node metastases had significant staining
for UBE2C protein.
UBE2C Expression Confirmed on Western Blot Analysis
Western blot analysis was used to confirm TMA results
for tumors S96-T, M48-T, K32-T, and P28-T showing an
expression of a 19-kDa protein consistent with UBE2C
(Figure 3A). In contrast, only small amounts of UBE2C
protein were found in the Barrett’s metaplasia sample
M48-B and in the normal esophageal sample M48-N. There
was no UBE2C protein expressed in the Barrett’s dysplasia
sample S96-BD or in the normal esophageal samples A54-N
and D67-N (Figure 3A).
Nine esophageal cell lines, including seven cell lines
derived from esophageal adenocarcinoma, were evaluated
for UBE2C protein expression by Western blot analysis.
As shown in Figure 3B, the esophageal adenocarcinoma–
derived cell lines BA, OE33, Flo-1, Seg-1, and Bic-1 ex-
pressed UBE2C protein, whereas the tumor-derived lines
L20-Tand H80-T showed lesser amounts of UBE2C protein.
TheSV40-immortalized squamous lineHet-1A and theE6/E7
immortalized Barrett’s metaplasia–derived S95-B cells also
expressed UBE2C protein.
Figure 1. Oligonucleotide microarray analysis of 46 esophageal samples revealed at least a two-fold overexpression ( Y axis) of UBE2C in 11 of 15 (73%) cases of
esophageal adenocarcinomas relative to Barrett’s metaplasia. BM, Barrett’s metaplasia; LGD, low-grade dysplasia; HGD, high-grade dysplasia; EA, esophageal
adenocarcinoma. Numbers on X axis labels represent tumor ID.
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Seg-1 Transfection with Dominant-Negative UBE2C
Decreased Cell Proliferation
The dominant-negative UBE2C was subcloned and ex-
panded in AG1 bacteria, and the insert was analyzed by DNA
sequencing, confirming the expected dominant-negative
UBE2C sequence encoding a cysteine-to-serine mutation
at residue 114. The dominant-negative insert was also
confirmed by double enzymatic digest. Wild-type UBE2C
contains an internal NdeI restriction site that is lost in the
dominant-negative insert due to a T-to-A base change. Seg-1
cells, which originally overexpressed wild-type UBE2C,
showed a significant 24% decrease in cell proliferation
48 hours after transfection with the dominant-negative
UBE2C when compared to control cultures using the MTT
assay (P < .05) (Figure 4A). The transfection efficiency
was 67% and was not significantly different between vector
controls and plasmids containing dominant-negative UBE2C
(Figure 4B). However, 64% of cells were in the mitotic
Table 1. Immunohistochemical Analysis of UBE2C Expression in Esoph-
ageal Tissues Using TMA*.
UBE2C Staining
Barrett’s metaplasia 0/8 (0%)
Dysplasia 7/10 (70%)
Adenocarcinoma 58/67 (87%)
Lymph node metastases 7/8 (88%)
*Significant staining includes moderate to intense staining (scores: 2 of 3;
3 of 3).
Figure 2. TMA immunohistochemistry showing (A) intense nuclear staining (arrow) in tumor D48-T, (B) intense staining (arrow) in esophageal adenocarcinoma
R35-T, (C) moderate staining (arrow) in Barrett’s dysplasia sample P60-BD, and (D) no staining in Barrett’s metaplasia sample I93-B. Original magnification, 200.
Sections were counterstained with hematoxylin.
Figure 3. (A)Western blot analysis shows expression of UBE2C (f19 kDa) in
esophageal adenocarcinomas S96-T, M48-T, K32T, and P28-T. The Barrett’s
metaplasia sample M48-B and the normal esophageal sample M48-N ex-
press small amounts of UBE2C, whereas there was no UBE2C protein
expressed in either the Barrett’s dysplasia sample S96-BD or the normal
esophageal samples A54-N and D67-N. (B) Western blot analysis of nine
esophageal cell lines shows expression of UBE2C (f19 kDa) in the esoph-
ageal adenocarcinoma cell lines BA, OE33, Flo-1, Seg-1, and Bic-1, whereas
L20-T and H80-T showed smaller amounts of UBE2C protein. The squamous
cell line Het-1A and the Barrett’s metaplasia–derived S95-B also expressed
UBE2C protein. -Actin expression was used as loading control.
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phase after transfection with dominant-negative UBE2C,
which was significantly higher than the 7% seen with vector
controls (P < .005).
Seg-1 Cells Are Sensitive to the Proteasome
Inhibitor MG-262
After treatment with the proteasome inhibitor MG-262,
Seg-1 cells showed a significant decrease in cell proliferation
at higher doses of 500 nM and 1 mM when compared to
control cultures using the MTTassay (P < .05) (Figure 4C).
siRNA Targeting UBE2C Potently Inhibits
UBE2C Expression
Seg-1 cells that overexpress UBE2C were grown at 1.5 
103 and 2.5  103 cells/well in a 96-well format and trans-
fected with 10 nM of either siGENOME SMARTpool UBE2C
or relative control 24 hours after cell seeding. Cell toxicity was
monitored, and no difference was detected between trans-
fectants compared to untreated or mock cells (data not
shown). Real-time quantitative RT-PCR revealed a potent
gene silencing of UBE2C. A difference from four to five
threshold cycles (Ct) between mock control and cells treated
with UBE2C-specific siRNA and > 95% reduction of UBE2C
mRNA in both 1.5  103 and 2.5  103 transfectants were
detected (Figure 5, A and B). The gene-silencing efficiency
of UBE2C mRNA expression consistently ranged from 92%
to 95% among cells treated for 24, 48, 72, and 96 hours.
Global siRNA inhibition was monitored using nontargeting
siRNA transfection and was not detected in our experiments
(Figure 5B). Cells transfected with UBE2C-specific siRNA
were harvested at different time points, and protein was
extracted.Western blot analysis revealed a complete UBE2C
blockage, as shown in Figure 5C.
Reduction of Cell Proliferation in Seg-1 Cells Transfected
with UBE2C-Specific siRNA
When WST-1 cell proliferation assay was performed on
UBE2C-specific siRNA transfectants, a 39.9% (2.5  103)
to 44.3% (1.5  103) reduction in cell proliferation was ob-
served after 48-hour siRNA treatment compared to mock-
transfected cells (Figure 6). Decreased cell proliferation was
also seen in 24-hour and 72-hour transfectants that ranged
from > 20% to > 30%, respectively (Figure 6). There was no
difference in cell proliferation observed in either 96-hour
transfectants or 96-hour dual transfectants compared to
mock cells (Figure 6). However, this could be explained by
the fact that, after 96 hours, cells had reached confluence
and were no longer proliferating.
G2 Cells Reach Maximal Accumulation at 72 Hours
Following siRNA-Mediated UBE2C Silencing
Because UBE2C is a cyclin A–specific and cyclin B1–
specific E2 ubiquitin-conjugating enzyme, we speculated
that, after UBE2C is downregulated, the cell cycle might be
distorted and might arrest in G2-phase and/or M-phase ac-
cordingly. Figure 7 shows that G2 cell accumulation was
observed to reach the maximum at 72 hours (155.4% of
mock) but started to decrease 24 hours after siRNA-mediated
UBE2C silencing compared to mock cells that showed a
normal cell cycle distribution (Figure 7, A and B). Interest-
ingly, we observed that knocking down UBE2C could also
drastically increase S-phase cells (308% of mock) within
24 hours after siRNA treatment. In addition, 72 hours fol-
lowing siRNA-mediated UBE2C silencing with an additional
Figure 4. (A) Seg-1 cells, which overexpressed UBE2C, showed a significant
decrease in cell proliferation after transfection with the dominant-negative
UBE2C when compared to control cultures using the MTT assay. All ex-
periments were repeated in triplicate. (B) Although transfection efficiency was
not significantly different between vector controls and dominant-negative
UBE2C plasmids in Seg-1 cells, the percentage of cells in the mitotic phase
was significantly higher after transfection with the dominant-negative UBE2C.
All experiments were repeated in triplicate. (C) Seg-1 cells showed a sig-
nificant decrease in cell proliferation after treatment with the proteasome
inhibitor MG-262 when compared to control cultures using the MTT assay. All
experiments were repeated in triplicate (*P < .05, **P < .005).
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siRNA treatment at the 48-hour time point, cells also dem-
onstrated a sharp increase of S-phase cells (214.8% of mock
for dual treatment vs 117.1% of mock for single treatment)
(Figure 7A). PI labeling of cells for cytometric analysis also
suggested that apoptosis was minimal (0.01–0.08%) in cells
following siRNA treatment at various time points. Mitotic cells
with condensed chromatin was increased by 38% (P = .016)
in cells treated for 72 hours with siRNA against UBE2C
compared to mock cells (data not shown).
Discussion
In the current study, UBE2C was found to be overexpressed
in a large percentage of esophageal adenocarcinomas—in
Figure 5. UBE2C silencing with gene-specific siRNA treatment in Seg-1 cells. (A) Real-time quantitative RT-PCR indicated a potent knockdown of UBE2C mRNA
expression, with four to five threshold cycles (Ct) between mock control and siRNA-mediated UBE2C-silencing transfectants. (B) A > 95% reduction of UBE2C
mRNA expression was detected at 24 and 48 hours and in both 1.5  103 and 2.5  103 cells/well transfectants. (C) Western blot analysis of Seg-1 cells treated
with UBE2C-specific siRNA at various time periods. The lack of expression in the treated samples indicates complete abrogation of the UBE2C protein.
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11 of 15 (73%) at the mRNA level and in 58 of 67 (87%) at the
protein level—relative to Barrett’s metaplasia, suggesting
that therapeutic targeting against UBE2C may be applicable
to some patients with esophageal adenocarcinomas. Over-
expression of UBE2C also occurs relatively early in the
progression from Barrett’s metaplasia to esophageal adeno-
carcinoma, with overexpression in 2 of 15 (13%) Barrett’s
dysplasia samples at the mRNA level and in 7 of 10 (70%) at
the protein level. This suggests that targeting UBE2C might
also be applicable to premalignant lesions.
Cell-specific staining seen on TMA is likely related to the
cell cycle–dependent expression of UBE2C protein. UBE2C
is known to be involved in the regulation of the cell cycle,
and overexpression of UBE2C may reflect tumor-related in-
creases in cell proliferation. However, NIH3T3 cells trans-
fected with UBE2C have been shown to have an increased
rate of growth and colony formation, suggesting that UBE2C
may be important in cell transformation [9].
Figure 6. WST-1 cell proliferation assay. The reduction of cell proliferation in
Seg-1 cells treated with siRNA against UBE2C demonstrated a maximal
decrease of 44.3% compared to mock control cells. Cell proliferation was de-
creased in 22.4% and 31.0% of mock controls after the 24-hour and 72-hour
treatments, respectively, of siRNA-mediated UBE2C silencing. There was no
difference in cell proliferation observed between treated cells and mock cells
after 96 hours.
Figure 7. Flow cytometry of cells labeled with PI. (A) Change in cell cycle distribution over time was observed for Seg-1 cells following treatment with siRNA against
UBE2C. Maximal G2 cell accumulation was observed 72 hours after treatment with siRNA (155.4% increase compared to mock cells and/or a normal range of cell
cycle distribution). Shown also in this figure is that S-phase cell number increased significantly 24 hours after siRNA transfection. S-phase cells were also increased
in 72-hour transfectants treated with an additional siRNA transfection at the 48-hour time point (24 hours before harvest of 72-hour transfectants). (B) Cell cycle
distributions over time after siRNA treatment against UBE2C.
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UBE2C protein was expressed in several primary tumors
and esophageal adenocarcinoma–derived cell lines. The
squamous cell line Het-1A and the Barrett’s metaplasia–
derived cell line S95-B also expressed UBE2C protein on
Western blot analysis. This may be due to the fact that these
are SV40-immortalized and E6/E7–immortalized cell lines,
respectively. In contrast, the primary Barrett’s metaplastic
tissue samples did not express high levels of UBE2C mRNA
or protein based on oligonucleotide microarray, Western blot,
and immunohistochemical analyses.
Transfection of Seg-1, an esophageal adenocarcinoma–
derived cell line expressing high levels of UBE2C, with a
dominant-negative form of UBE2C resulted in a significant
decrease in cell proliferation compared to control cultures.
Mutation of the active site cysteine to serine results in a
dominant-negative phenotype [5,6]. Although the dominant-
negative UBE2C can accept ubiquitin, the enzyme is not as
efficient as the wild-typeUBE2C due to the low free energy of
hydrolysis of the ester bond compared to the thioester bond
formed by wild type. The dominant-negative phenotype may
also be the result of the mutant UBE2C being bound non-
productively to the APC [4].
Dominant-negative UBE2C inhibits destruction of cyclins
A and B with cells arresting in M-phase. In the current study,
64% of transfected cells were arrested in the mitotic phase
compared to only 7% of the cells transfected with vector
controls, despite similar transfection efficiencies. Townsley
et al. [5] reported similar findings showing that 50% of cells
transfected with dominant-negative UBE2C showed cell
cycle arrest compared to only 2% of controls. There was in-
complete inhibition of cell cycle progression because > 35%
of cells remained in interphase. In an earlier study, even a
10-fold excess of dominant-negative UBE2C resulted in only
a 90% inhibition of UBE2C, with a 20-fold excess necessary
for complete inhibition [5]. Inhibition of UBE2C may become
an important therapeutic approach in cancers such as esoph-
ageal adenocarcinoma and may be even more effective
when used in combination with therapies targeting other
pathways. Wagner et al. [25] found that the combination of
UBE2C siRNA and DR5/TRAIL receptor agonists signifi-
cantly enhanced the killing of cancer cells.
Although no specific UBE2C inhibitors are currently avail-
able for clinical use, proteasome inhibitors form a novel class
of chemotherapeutic agents that lead to cell cycle arrest and
cell death. Tumor cells are more susceptible to proteasome
inhibition due to their rapid division and disordered regulatory
pathways, and bortezomib has now been approved for the
treatment of advanced multiple myeloma. MG-262 is a cell-
permeable reversible proteasome inhibitor (Ki = 0.023 nM)
of the peptide boronate class that inhibits the chymotrypsin-
like activity of proteasome [26]. When treated with MG-262,
Seg-1 cells showed significant decreases in cell proliferation
at higher doses of 500 nM and 1 mM when compared to
control cultures (Figure 4C), although this did not reach 50%
growth inhibition. Although Seg-1 cells expressed high levels
of UBE2C, as did the majority of the esophageal cell lines
available, L-20T and H80-T expressed low levels of UBE2C.
Unfortunately, we were unable to analyze the effect of
MG-262 on these cell lines due to their slow growth rate,
which was on the order of months. However, this correlation
between lower levels of UBE2C expression and a slower rate
of growth suggests that UBE2C may be important in tumor
cell proliferation.
Consistent with results from dominant-negative UBE2C
transfection in Seg-1 cells, reduction of cell proliferation was
observed up to 72 hours after siRNA-mediated UBE2C
silencing in the same cell line. UBE2C mRNA expression
was nearly completely silenced up to 96 hours after siRNA
treatment. We included two controls with additional transfec-
tion of siRNA at the 48-hour time point for 72-hour and
96-hour groups; both single transfectants and dual trans-
fectants showed nearly complete blockage of UBE2CmRNA
and protein expression assayed using real-time RT-PCR and
Western blot analysis. The greatest decrease in cell prolifer-
ation compared to mock cells was observed after 48 hours of
siRNA treatment (44% reduction). However, cell cycle distor-
tion was more complex after UBE2C was silenced because
UBE2C is equally crucial for the degradation of the two
distinct cyclins, cyclins A and B1 [5,6,27]. We observed a
slight increase in G2 cells after 72-hour siRNA treatment as
expected, but surprisingly, there was a sharp increase in
S-phase cell accumulation 24 hours after siRNA-mediated
UBE2C silencing. Both cyclin A and cyclin B1 are M-phase
cyclins that engage cells to enter M-phase from G2-phase;
timely degradation of the two cyclins leads cells to exit
M-phase to G1-phase for the next round of the cell cycle
[28]. Girard et al. [29] suggested that cyclin A might be
involved in DNA replication as they observed that silencing
cyclin A in G1-phase triggered inhibition of DNA synthesis.
More recently, Mihaylov et al. reported that silencing of
cyclin A, but not of cyclin B, led to complete duplication of
genome from 4N to 8N. They analyzed cyclin A and geminin
double knockouts and determined that the effect of cyclin A
deficiency on cell cycle arrest and overreplication was dom-
inant over that of geminin deficiency. The authors concluded
that both cyclin A and geminin were required for the suppres-
sion of overreplication in Drosophila cells [30]. Neither
G1-phase cyclin A silencing causing the onset of DNA syn-
thesis nor the requirement of cyclin A to suppress overrepli-
cation may account for our observation of a sharp increase in
S-phase cells 24 hours after siRNA-mediated UBE2C silenc-
ing. It may, however, be better explained by the unmasking of
a cyclin B1 S-phase–promoting potential due to a decrease
in cyclin B1 degradation following UBE2C silencing [31].
UBE2C expression has not been previously described in
esophageal adenocarcinoma. This study characterizes the
expression of UBE2C at mRNA and protein levels, providing
a potential target in a subset of patients whose tumors
express high levels of UBE2C in a type of a cancer with
few successful treatments currently available. Esophageal
adenocarcinoma–derived cells expressing UBE2C, as well
as a dominant-negative form of UBE2C or UBE2C-specific
siRNA, are sensitive to treatment with MG-262, suggesting
that patients with esophageal adenocarcinomas expressing
high levels of UBE2C may benefit from agents that target
this ubiquitin-conjugating enzyme.
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